CCL2 and type 2 diabetes mellitus: The combination of PPARγ and PPARα agonists also inhibited inflammatory cytokine secretion in the T2DM patients with CAD and attenuated the LPS-induced MCP-1 secretion by PBMCs in the T2DM patients.